Neoadjuvant <i>Nab</i>-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX - Concepedia

Concepedia

Publication | Open Access

Neoadjuvant <i>Nab</i>-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX

DOI Full Paper Access

16

Citations

10

References

2018

Year

Shawn Peterson, Muhammad Husnain, Terri Pollack, Agustin Pimentel, Arturo Loaiza‐Bonilla, Colleen Westendorf-Overley, Kelley L. Ratermann, Lowell Anthony, Gaurav Goel, Mahesh Kudrimoti,

Anticancer Research

Abstract

In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.

References

	Year	Citations

Page 1